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Abstract:  Changes in hormone metabolism during menopause are involved in the development of osteoporosis and 
arterial hypertension. A mutual influence of these two clinical pictures is evident on the basis of pathophysiological 
factors. 
In this study, we investigated whether a drug therapy of hypertension influences the efficacy of a bisphosphonate 
(alendronate) in the treatment of postmenopausal osteoporosis. For this purpose, 60 female patients were enrolled in the 
study, 30 of them on drug treatment for hypertension in addition to requiring treatment for osteoporosis, while the control 
group was only suffering from osteoporosis. 
Bone density was measured at the start of the study and 6 months after therapy (QCT). 
A significant increase in bone density was demonstrated in both groups, while a difference between the groups could not 
be seen. 
Treated arterial hypertension does not have a negative influence on the treatment of postmenopausal osteoporosis with 
alendronate. Rather, the concomitant treatment of these two clinical pictures would appear to make sense, in order to 
reduce morbidity and mortality. 
Keywords: Osteoporosis, hypertension, alendronate, bisphosphonate. 
INTRODUCTION 
  The menopause is a risk factor in the development of 
cardiovascular diseases and osteoporosis [1]. Hormonal 
changes as part of the aging process in women, with a 
reduction in oestrogen and progesterone, are the cause [2]. 
Hormone replacement therapy would therefore appear to 
make sense for prevention. Combination prophylaxis with 
oestrogen and progesterone led to an increase in bone 
density and a reduction of the fracture risk [3], but did not 
show a reduction in the incidence of myocardial infarction 
and tripled the risk of thrombosis (HERS-II study) [4]. 
Further studies showed an increase in the risk of breast 
cancer (WHI study) [2], so that, despite being a causative 
approach, the prophylaxis of postmenopausal cardiovascular 
diseases and osteoporosis with hormone replacement is no 
longer a standard therapy. Instead, the independent sympto-
matic therapy of osteoporosis and metabolic syndrome 
(hypertension, hypercholesterolaemia and hyperglycaemia) 
is recommended, since untreated hypertension is the main 
cause of cardiovascular events [5, 6]. 
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  On the basis of the data available and the pathophysio-
logical factors, a mutual influence of hypertension and 
osteoporosis is evident. The occurrence of pathological 
fractures that accompanies reduced bone density is 
associated with cardiovascular diseases [7]. An imbalance in 
calcium metabolism plays a role in the pathophysiology of 
hypertension [8, 9]. Since bone is the largest calcium store in 
the human body, the bone mineral salt content can be 
changed pathologically by the release of calcium from the 
bone. Osteoporosis could thus be induced by untreated 
hypertension [7, 10]. This clinical observation is additionally 
supported by the findings of Bastos et al. on spontaneous 
hypertensive rats that presented a reduced bone quality and 
elevated bone resorption markers [11]. On the other hand it 
recently has been shown, that Beta-blockers are 
independently associated with fragility fractures [12]. In 
contrast Olmos et al. recently showed that bone mineral 
density was increased by thiazides in hypertensive 
postmenopausal women [13]. Up to now, it has been unclear 
whether antihypertensive therapy influences the efficacy of 
drug therapy for osteoporosis. The objective of this study 
was, therefore, to elucidate whether female patients treated 
with antihypertensives who are suffering from 
postmenopausal osteoporosis benefit to the same extent from 
treatment with a bisphosphonate as female patients without 
hypertension. 
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METHODS 
  Sixty female patients suffering from postmenopausal 
osteoporosis were enrolled in this monocentric, prospective, 
non-blind, controlled study. This study was conducted in an 
orthopaedic practice after written approval from the ethics 
committee. To begin with, the files were inspected for 
patient selection. If there was anamnestic or clinical evidence 
of osteoporosis, a bone density measurement was taken by 
means of QCT. The DVO-REKO osteoporosis risk 
questionnaire was completed by all female patients who 
came into question. This questionnaire covers the following 
risk factors for osteoporosis: reduction in height, acute 
backache, increased tendency to fall over, peripheral 
fractures after bagatelle trauma, relatives with osteoporosis, 
medical history of femoral head fractures, intake of 
glucocorticoids, presence of a chronic inflammatory 
intestinal disease, reduction of physical activity, 
underweight, calcium intake < 1000 mg/ d, fish < 2x/ week, 
menopause before the age of 45 years). 
  If the diagnosis of postmenopausal osteoporosis was 
confirmed by a bone density of less than 80 mg/ ml calcium 
hydroxylapatite [14] and at least one positive response in the 
DVO-REKO osteoporosis risk questionnaire, the patients 
were enrolled in the study after giving their consent. The 
patients were subsequently allocated to the study groups 
depending on whether or not they were receiving drug 
therapy for hypertension and the kind of medication was 
documented. Systolic and diastolic blood pressure were 
measured in all patients before and after therapy. Exclusion 
criteria were the presence of secondary osteoporosis, the 
regular intake of glucocorticoids, chronic inflammatory 
diseases of the gastrointestinal tract, renal dysfunction, 
unstable arterial hypertension, secondary hypertension, 
condition after myocardial infarction or stroke, known 
hypocalcaemia or osteomalacia. 
  All patients enrolled received basic therapy of their 
osteoporosis with alendronate as directed, with additional 
substitution of calcium and vitamin D (DVO guideline 
2006). 
  Bone density was determined again by means of QCT 6 
months after inclusion in the study. 
  A visual analogue scale (VAS) was used to measure pain 
intensity, and the IOF-41-Qualeffo score at baseline and at 
the 6-month follow up was recorded to determine quality of 
life [15]. The latter consists of a total of 41 questions that 
cover the different aspects that account for quality of life 
(pain, mobility, leisure time, perception of health, mood). 
The score is standardised to a percentage result by means of 
the following formula: 
(current score - 41) x 100 
         164 
  A high percentage value indicates a strong burden caused 
by osteoporosis. 
  A power analysis was performed and based on a bone 
mineral density difference of 10 mg/ml that is considered to 
be clinically relevant and should therefore be detected in the 
intergroup comparison. The expected BMD of osteoporosis 
patients was set to 50 ± 15 mg/ml resulting from empirical 
data of the authors last years of clinical practice. Defining a 
level of significance of 0.05 and a power of 80 %, this 
resulted in a required sample size of 30 patients per group. 
RESULTS 
  Sixty female patients were enrolled in this study. The 
mean age in the control group was 67.3 years (49 - 80 years) 
and in the hypertension group 71.2 years (58 - 82 years) [p = 
0.021]. In the control group, the mean systolic blood 
pressure was 122 (100 – 140) mmHg and the mean diastolic 
value 78 (70 - 90) mmHg before therapy. Likewise in the 
hypertension group, as a result of the drug therapy, the mean 
systolic value was 135 (120 - 160) mmHg and the mean 
diastolic value 81 (75 - 90) mmHg before the start of the 
study. After therapy, the mean systolic blood pressure in the 
hypertension group was 133 (115 - 170) mmHg and the 
mean diastolic value 79 (70 - 90) mmHg. This corresponds 
to upper normal values according to the guidelines of the 
Deutsche Hochdruckliga (German Hypertension League). 
The kind of antihypertensive medication is given in Table 1. 
Table 1.  Baseline Characteristics of the Study Collective 
 
 Hypertension  Control  p-Value 
Age [years]  71.2 (58 – 82)  67.3 (49 – 80)  0.021 
Systolic Blood  
Pressure  
[mmHg] 
135 (120 - 160)  122 (100 – 140)  n.s 
Diastolic Blood  
Pressure [mmHg] 
81 (75 - 90)  78 (70 – 90)   n.s. 
Bone Mineral  
Density [mg/dl] 
56.2 (37.0 - 79.3)  50.0 (22.2 – 75.9)  n.s. 
 
  In the control group, the mean systolic values were 121 
(100 – 135) mmHg and the mean diastolic values 78 (70 – 
80) mmHg. This corresponds to normal blood pressure 
values. The systolic blood pressure values did not differ 
significantly between the two groups before and after 
alendronate therapy (Fig. 1). 
 
Fig. (1). Systolic and diastolic blood pressure before and after 
alendronate therapy. 
  Bone density in the hypertension group was 56.2 mg/ dl 
(37.0 – 79.3 mg/ dl) at the start of the study and increased 
within 6 months over the course of therapy with alendronate 
to 59.9 mg/ dl (32 - 82 mg/ dl) [p = 0.002]. In the control 
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group, bone density was 50.0 mg/ dl (22.2 – 75.9 mg/ dl) 
before therapy and increased to 55.9 mg/ dl (30 – 81.9 mg/ 
dl) (p < 0.001; Fig. 2). However, if one compares the 
hypertension group and the control group, significant 
differences in bone density are not to be found, either at the 
start of the study or at follow up. 
Fig. (2). Bone density before and after alendronate therapy 
  In the therapy of osteoporosis-associated pain, again a 
significant improvement could be shown in both groups over 
the course of the study. The VAS decreased over the 
observation period from 55 mm to 41 mm [p < 0.001] in the 
control group and from 61 mm to 42 mm (p < 0.001; Fig. 3) 
in the hypertension group. The IOF-41-Qualeffo has a 
domain that reflects the subjects' subjective pain perception. 
Here, the patients in the control group showed a reduction of 
53 (5 - 85) to 46 (5 - 80) points. In the hypertension group, 
the values changed from 48 (0 - 90) to 39 (0-80) points [p < 
0.001]. However, no significant differences could be found 
between the two groups before and after therapy in the IOF-
41-Qualeffo/ pain or in the VAS. 
 
Fig. (3). Visual analogue scale before and after alendronate therapy. 
  If one compares the other domains of the IOF-41-
Qualeffo and their total before and after therapy separately 
for the two treatment groups, an improvement in quality of 
life in all individual domains and in their total as a result of 
the alendronate therapy could be demonstrated for the 
hypertension group. There were also significant 
improvements in the individual domains in the control 
group, with the exception of the "mood" domain (Fig. 4). 
 
Fig. (4). IOF-41-Qualeffo score 6 months after alendronate therapy. 
  If one compares the results of the hypertension and 
control group, again no differences are to be found in the 
IOF-41-Qualeffo. Here, the hypertension group already 
showed significantly higher values in the sub-domains 
leisure time and mood before therapy, compared with the 
control group [p = 0.005 and p = 0.025]. These group 
differences were not affected by the therapy (p = 0.008 and  
p = 0.015; Fig. 4). 
  Taking the patients age and the sub-domains leisure time 
and mood of the IOF-41-Qualeffo as confounding variables 
into account all group comparisons were re-calculated but 
did not result in any new statistically significant difference in 
terms of blood pressure, BMD, VAS, IOF-41-Qualeffo. The 
kind of antihypertensive medication did not statistically 
significantly influence any of the examined parameters. 
DISCUSSION 
  The results presented here show that a drug treatment of 
arterial hypertension does not have any negative influence on 
the treatment of postmenopausal osteoporosis with 
alendronate. Clinical studies have demonstrated that there is 
a connection between cardiovascular diseases and an 
increased risk of fracture. Thus, Schulz et al. showed that 
aortal calcification is accompanied by a 3-fold higher risk of 
femoral head fracture [16]. In the reverse case, Tanko et al. 
showed that osteoporosis patients have a 4-fold higher risk 
of suffering a stroke or myocardial infarction than patients 
with osteopaenia [1]. Other working groups have shown that 
there is a connection between cardiovascular diseases and 
the loss of bone mass [17, 18]. 
  A therapy of osteoporosis and hypertension would 
therefore appear to be essential in order to reduce the risk of 
cardiovascular as well as osteoporotic morbidity and 
mortality [1, 19, 20]. 
  There is widespread evidence of a mutual interaction of 
the two clinical pictures [7-10]. 
  There is evidence of a molecular biological origin of the 
coincidence of osteoporosis and hypertension. The two 
diseases are linked via the RANKL/RANK/osteoprotegerin 
system. Osteoprotegerin is a glycoprotein that belongs to the 
group of the tumour necrosis factor receptor superfamily and 
can prevent a differentiation of the precursor cells of 
osteoclasts and thus osteoporosis [21, 22]. Reduced 
osteoprotegerin leads to a reduction in bone density and can 
lead to arteriosclerosis [23]. 
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  The hormone oestrogen, which is reduced in 
postmenopausal osteoporosis, can lead to a reduction in bone 
density and have an influence on atherogenesis via  the 
release of cytokines (IL-1, IL-6 and TNF-alpha) and also via 
a reduction of osteoprotegerin [24]. 
  The study presented here collected purely clinical data 
and did not investigate calcium metabolism or determine 
osteoprotegerin levels. 
  In our study group, the patients of the hypertension group 
did not have reduced bone density compared with the control 
group, either in the baseline situation or after therapy with 
alendronate. 
  In accordance with the literature, we were able to show 
that bone density already increased after 6 months' initial 
therapy with a bisphosphonate [25]. The presence of arterial 
hypertension did not have any influence on the therapeutic 
outcome. 
  A reduction in pain and an improvement in quality of life 
could be shown in both groups over the follow-up period. 
This is consistent with the results of Dursun et al., who also 
showed a reduction in osteoporosis-associated pain and an 
improvement in quality of life under therapy with a 
bisphosphonate in the treatment of postmenopausal 
osteoporosis [26]. The presence of arterial hypertension did 
not have an influence on the pain reduction or the 
improvement in quality of life after alendronate therapy. 
  Limitations of the study are the non-randomized, non-
blind design and the limited number of cases. Possibly 
confounding variables that showed differences between the 
groups before therapy were the patients’ age and subdomains 
of the IOF-41-Qualeffo score resulting from the non-
randomized study design. This was statistically addressed by 
a re-calculation taking these possible confounders into 
account but did not alter the conclusions. 
  The follow-up period was long enough to detect 
therapeutical effects of both, antihypertensive and 
osteoporosis therapy but it remains unclear whether 
antihypertensive therapy may influence the efficacy of 
alendronate in the long term (Table 2). 
Table 2.  Antihypertensive  Therapy  in  the 
Hypertension  Group (16 Patients had a 
Monotherapy, 10 Patients Received a Double 
Combination, Three Patients a Triple Combination, 
and Two Patients a Quadruple Combination of 
Antihypertensive Drugs) 
 
Antihypertensive Medication  Patients 
Beta-Blocker 18 
Calcium Antagonist  10 
ACE Inhibitor  9 
Diuretic 5 
Nitrate 5 
Angiotensin II Antagonist  3 
 
  Although fracture incidence is a clinically more relevant 
outcome parameter for a successful osteoporosis therapy the 
change of bone mineral density was chosen in this study 
based on the fact that it shows quantitative effects on small 
patient collectives and is more robust against confounding 
variables (e.g. risk of falling, neurological disorders). 
  Based on the results, hypertension under drug therapy 
does not have a negative influence on a 6 month treatment of 
postmenopausal osteoporosis with alendronate. Rather, a 
good drug therapy of these two diseases would appear to 
make sense, in order to reduce their morbidity and mortality. 
REFERENCES 
[1]  Tanko LB, Christiansen C, Cox DA, et al. Relationship between 
osteoporosis and cardiovascular disease in postmenopausal women. 
J Bone Miner Res 2005; 20: 1912-20. 
[2]  Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits 
of estrogen plus progestin in healthy postmenopausal women: 
principal results from the Women's Health Initiative randomized 
controlled trial. JAMA 2002; 288: 321-33. 
[3]  Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus 
progestin on risk of fracture and bone mineral density: the 
Women's Health Initiative randomized trial. JAMA 2003; 290: 
1729-38. 
[4]  Grady D, Herrington D, Bittner V, et al. Cardiovascular disease 
outcomes during 6.8 years of hormone therapy: Heart and 
Estrogen/progestin Replacement Study follow-up (HERS II). 
JAMA 2002; 288: 49-57. 
[5]  Vitale C, Miceli M, Rosano GM. Gender-specific characteristics of 
atherosclerosis in menopausal women: risk factors, clinical course 
and strategies for prevention. Climacteric 2007; 10(Suppl 2): 16-
20. 
[6]  Rosano GM, Vitale C, Tulli A. Managing cardiovascular risk in 
menopausal women. Climacteric 2006; 9(Suppl 1): 19-27. 
[7]  Cappuccio FP, Meilahn E, Zmuda JM, et al. High blood pressure 
and bone-mineral loss in elderly white women: a prospective study. 
Study of Osteoporotic Fractures Research Group. Lancet 1999; 
354: 971-5. 
[8]  Power ML, Heaney RP, Kalkwarf HJ, et al. The role of calcium in 
health and disease. Am J Obstet Gynecol 1999; 181: 1560-9. 
[9]  Zittermann A, Schleithoff SS, Koerfer R. Putting cardiovascular 
disease and vitamin D insufficiency into perspective. Br J Nutr 
2005; 94: 483-92. 
[10]  von der Recke P, Hansen MA, Hassager C. The association 
between low bone mass at the menopause and cardiovascular 
mortality. Am J Med 1999; 106: 273-8. 
[11]  Bastos MF, Brilhante FV, Gonçalves TE, et al. Hypertension may 
affect tooth-supporting alveolar bone quality: a study in rats. J 
Periodontol 2010; 81(7): 1075-83. 
[12]  Sosa M, Saavedra P, Mosquera J, et al., GIUMO Cooperative 
Group. Beta-blocker use is associated with fragility fractures in 
postmenopausal women with coronary heart disease. Aging Clin 
Exp Res 2010; [Epub ahead of print]. 
[13]  Olmos JM, Hernández JL, Martínez J, et al. Bone turnover markers 
and bone mineral density in hypertensive postmenopausal women 
on treatment. Maturitas 2010; 65(4): 396-402. 
[14]  Banzer D, Felsenberg D. Computerized tomography determination 
of bone mineral content in quantitative diagnosis of osteoporosis. 
Orthopade 1989; 18(1): 12-7. 
[15]  Lips P, Cooper C, Agnusdei D, et al. Working Party for Quality of 
Life of the European Foundation for Osteoporosis. Quality of life 
in patients with vertebral osteoporosis. Validation of the quality of 
life questionnaire of the European Foundation for Osteoporosis 
(Qualeffo). Osteoporosis Int 1999; 10: 150-60. 
[16]  Schulz E, Arfai K, Liu X, et al. Aortic calcification and the risk of 
osteoporosis and fractures. J Clin Endocrinol Metab 2004; 89: 
4246-53. 
[17]  Pennisi P, Signorelli SS, Riccobene S, et al. Low bone density and 
abnormal bone turnover in patients with atherosclerosis of 
peripheral vessels. Osteoporos Int 2004; 15: 389-95. 
[18]  Kiel DP, Kauppila LI, Cupples LA, et al. Bone loss and the 
progression of abdominal aortic calcification over a 25 year period: 
the Framingham Heart Study. Calcif Tissue Int 2001; 68: 271-6. Treated Hypertension has No Influence on the Efficacy of Alendronate  The Open Orthopaedics Journal, 2011, Volume 5    31 
[19]  Marcovitz PA, Tran HH, Franklin BA, et al. Usefulness of bone 
mineral density to predict significant coronary artery disease. Am J 
Cardiol 2005; 96: 1059-63. 
[20]  Bevilacqua M, Dominguez LJ, Rosini S, et al. Bisphosphonates 
and atherosclerosis: why? Lupus 2005; 14: 773-9. 
[21]  Schoppet M, Preissner KT, Hofbauer LC. RANK ligand and 
osteoprotegerin: paracrine regulators of bone metabolism and 
vascular function. Arterioscler Thromb Vasc Biol 2002; 22: 549-
53. 
[22]  Collin-Osdoby P. Regulation of vascular calcification by osteoclast 
regulatory factors RANKL and osteoprotegerin. Circ Res 2004; 95: 
1046-57. 
[23]  Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin-deficient 
mice develop early onset osteoporosis and arterial calcification. 
Genes Dev 1998; 12: 1260-8. 
[24]  McFarlane SI. Bone metabolism and the cardiometabolic 
syndrome: pathophysiologic insights. J Cardiometab Syndr 2006; 
1: 53-7. 
[25]  Hosking D, Chilvers CE, Christiansen C, et al. Prevention of bone 
loss with alendronate in postmenopausal women under 60 years of 
age. Early Postmenopausal Intervention Cohort Study Group. N 
Engl J Med 1998; 338: 485-92. 
[26]  Dursun N, Dursun E, Yalcin S. Comparison of alendronate, 
calcitonin and calcium treatments in postmenopausal osteoporosis. 
Int J Clin Pract 2001; 55: 505-9. 
 
 
Received: April 22, 2010  Revised: July 12, 2010  Accepted: November 25, 2010 
 
© Matziolis et al.; Licensee Bentham Open. 
 
This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-
nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited. 
 
 
 
 